Yuvan Thakkar, a teenager of Indian descent battling cancer, expresses gratitude for the life-altering treatment, that enabled him to pursue his passions. The UK’s National Health Service initiated a fund to render innovative therapies accessible to numerous patients. NHS England highlights Thakkar as the inaugural beneficiary of the pioneering CAR T therapy, tisagenlecleucel (Kymriah), through its Cancer Drugs Fund (CDF).
Dear Readers,
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
